Early-stage research services including pharmacology, toxicology, and proof-of-concepts studies
Assessment of compound-induced cell toxicity and viability using standardized in vitro models to support early safety evaluation.
Analysis of cell growth patterns and cell-cycle progression to understand compound effects on cellular replication.
Evaluation of apoptosis, necrosis, and DNA damage responses to determine cellular stress and damage mechanisms.
In vitro assays to study cell migration and invasion behavior relevant to cancer metastasis and tissue repair.
Advanced three-dimensional cell culture models that better mimic in vivo tissue architecture and function.
Assessment of pro- and anti-angiogenic activity by measuring endothelial cell growth and tube formation.
Qualitative and quantitative analysis of protein expression, structure, and functional activity in cell systems.
Isolation of high-quality genomic DNA from biological samples for downstream molecular applications.
Purification of intact RNA to support gene expression analysis and transcriptomic studies.
Quantitative PCR analysis for accurate measurement of DNA targets across multiple sample types.
Reverse transcription quantitative PCR for sensitive detection and quantification of RNA expression levels.
Genetic variation analysis through single nucleotide polymorphism profiling for research and biomarker studies.
Cell-based functional assays to evaluate anticancer activity, signaling pathways, and cellular response.
Assessment of compound effects on cardiac cell function, contractility, and viability.
Functional assays using airway and lung cell models to study respiratory efficacy and toxicity.
Cell-based evaluation of immune activation, cytokine release, and inflammatory signaling pathways.
Functional neuronal cell assays to assess neuroactivity, neuroprotection, and cytotoxicity.
Cell-based metabolic assays to evaluate insulin signaling, glucose uptake, and lipid metabolism.
Functional assays using muscle and bone cell models to study differentiation and cellular performance.
Measurement of intracellular reactive oxygen species and antioxidant response in cell-based systems.
Skin and cosmetic cell-based assays to evaluate safety, irritation, and biological performance.
Enumeration of aerobic microorganisms to assess overall microbial load in test samples.
Quantification of total bacterial and fungal populations to ensure microbiological quality.
Targeted identification of specific pathogenic microorganisms using validated detection methods.
Evaluation of preservative systems to confirm their ability to control microbial growth over time.
Detection and quantification of endotoxins to ensure product safety and regulatory compliance.
Assessment of microbial sensitivity or resistance to antimicrobial agents.
Evaluation of antifungal efficacy against selected fungal strains under controlled conditions.
Measurement of a compound’s ability to prevent or disrupt microbial biofilm formation.
Molecular identification and characterization of microorganisms based on genetic markers.
Microbiological assessment supporting drug absorption, distribution, and biological activity studies.
Initial screening of compound toxicity using general cell viability and cytotoxicity endpoints.
Evaluation of potential adverse effects on cardiac cells and functional cardiac markers.
In vitro assessment of ocular irritation potential using alternative test models.
Assessment of liver-specific toxicity through hepatocyte-based in vitro models.
Evaluation of compound effects on neuronal cells and neuro-specific toxicity markers.
Detection of pyrogenic responses to assess fever-inducing potential of test substances.
Assessment of toxic effects on respiratory epithelial cells and airway models.
Evaluation of potential adverse effects on reproductive cells and related biological pathways.
In vitro testing to assess irritation potential on reconstructed human skin models.
Assessment of sensitization potential to identify compounds that may trigger allergic skin reactions.
Evaluation of DNA damage and mutation potential to assess genetic safety risks.
In vivo tumor models used to evaluate antitumor efficacy, disease progression, and therapeutic response.
Animal models to assess cardiovascular function, safety, and efficacy of investigational compounds.
Evaluation of immune response modulation and anti-inflammatory activity using validated in vivo models.
In vivo respiratory disease models to study airway function, inflammation, and pulmonary safety.
Assessment of neuroprotective and neurotoxic effects using behavior and disease-relevant animal models.
Metabolic disease models for evaluating glucose regulation, lipid metabolism, and systemic energy balance.
In vivo models to study bone, muscle, and joint disorders, including efficacy and functional recovery.
Assessment of oxidative stress markers and antioxidant activity in relevant animal models.
In vivo evaluation of DNA damage and genetic safety to support regulatory toxicology requirements.
